Survival analysis of dogs with advanced primary lung carcinoma treated by metronomic cyclophosphamide, piroxicam and thalidomide
| Autor: | C. Rohrer Bley, Riccardo Finotello, K. Stiborova, Maria Elisabetta Vasconi, Laura Marconato, P Laganga, A. Barbanera, Silvia Sabattini, Federica Rossi, Gerry Polton |
|---|---|
| Přispěvatelé: | University of Zurich, Marconato, L, Polton, G., Finotello, R., Sabattini, S., Rossi, F., Laganga, P., Vasconi, M.E., Barbanera, A., Stiborova, K., Rohrer Bley, C., Marconato, L. |
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Male
Lung Neoplasms 10253 Department of Small Animals medicine.medical_treatment 3400 General Veterinary advanced stage Gastroenterology 0403 veterinary science 0302 clinical medicine Antineoplastic Combined Chemotherapy Protocols metronomic chemotherapy Dog Diseases 630 Agriculture 04 agricultural and veterinary sciences Combined Modality Therapy 030220 oncology & carcinogenesis Toxicity dog Veterinary (all) Female Survival Analysi Dog Disease prognosi medicine.drug medicine.medical_specialty Cyclophosphamide 040301 veterinary sciences canine Piroxicam 03 medical and health sciences Dogs Internal medicine thalidomide medicine Carcinoma Animals Survival analysis Chemotherapy Antineoplastic Combined Chemotherapy Protocol General Veterinary Animal business.industry medicine.disease Survival Analysis Metronomic Chemotherapy Lung Neoplasm Thalidomide Administration Metronomic 570 Life sciences biology prognosis business lung carcinoma |
| Popis: | Unresectable or metastatic (advanced) primary pulmonary carcinoma (PPC) represents a therapeutic challenge where surgery may be contraindicated and the therapeutic role of maximum-tolerated dose (MTD) chemotherapy remains uncertain. This study was undertaken to explore the impact of metronomic chemotherapy (MC) in dogs with advanced PPC. Previously untreated dogs with advanced (T3 or N1 or M1) PPC, with complete staging work-up and follow-up data, receiving MC (comprising low-dose cyclophosphamide, piroxicam and thalidomide), surgery, MTD chemotherapy or no oncologic treatment were eligible for inclusion. For all patients, time to progression (TTP) and survival time (ST) were evaluated. Quality-of-life (QoL) was only evaluated in patients receiving MC. To assess QoL, owners of dogs receiving MC were asked to complete a questionnaire before and during treatment. Ninety-one dogs were included: 25 received MC, 36 were treated with surgery, 11 with MTD chemotherapy and 19 received no treatment. QoL was improved in dogs receiving MC. Median TTP was significantly longer in patients receiving MC (172 days) than patients undergoing surgery (87 days), receiving MTD chemotherapy (22 days), or no oncologic treatment (20 days). Median ST was similarly longer in patients receiving MC (139 days) than those undergoing surgery (92 days), MTD chemotherapy (61 days) and no oncologic treatment (60 days). In dogs with advanced PPC, MC achieved a measurable clinical benefit without significant risk or toxicity. This makes MC a potential alternative to other recognized management approaches. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|